U.S. markets open in 7 hours 46 minutes
  • S&P Futures

    4,411.50
    -3.50 (-0.08%)
     
  • Dow Futures

    34,972.00
    -26.00 (-0.07%)
     
  • Nasdaq Futures

    15,052.00
    +5.75 (+0.04%)
     
  • Russell 2000 Futures

    2,213.60
    -5.80 (-0.26%)
     
  • Crude Oil

    70.38
    -0.18 (-0.26%)
     
  • Gold

    1,812.20
    +2.10 (+0.12%)
     
  • Silver

    25.72
    +0.13 (+0.52%)
     
  • EUR/USD

    1.1874
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.1760
    0.0000 (0.00%)
     
  • Vix

    18.04
    -1.42 (-7.30%)
     
  • GBP/USD

    1.3923
    +0.0008 (+0.06%)
     
  • USD/JPY

    109.0500
    0.0000 (0.00%)
     
  • BTC-USD

    38,108.55
    -160.50 (-0.42%)
     
  • CMC Crypto 200

    932.22
    -11.22 (-1.19%)
     
  • FTSE 100

    7,105.72
    +24.00 (+0.34%)
     
  • Nikkei 225

    27,575.81
    -66.02 (-0.24%)
     

Vir Biotech Soars as Covid Therapy Found Effective at Cutting Deaths

·1 min read

By Dhirendra Tripathi

Investing.com – Shares of Vir Biotechnology (NASDAQ:VIR) jumped 32% Thursday after the company said data showed its therapy, VIR-7831, had been found to be highly effective in the treatment of Covid-19 patients.

Vir developed the treatment jointly with GlaxoSmithKline (NYSE:GSK). The stock bounce brings Vir to a market value of almost $6 billion.

The two companies are working together to develop existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options for Covid-19.

Convinced of the treatment’s “profound efficacy” in reducing hospitalization and risk of death in early treatment of adults affected by the coronavirus, the Independent Data Monitoring Committee has asked the company to stop enrollment for the phase-3 trial.

The IDMC recommendation was based on an interim analysis of data from 583 patients enrolled in the trial, which demonstrated an 85% reduction in hospitalization or death in patients receiving the monotherapy compared to placebo, the primary endpoint of the trial.

VIR-7831 is an investigational compound, not approved by the U.S. Food and Drug Administration or any other regulatory authority. Its current development pipeline consists of product candidates targeting Covid-19, hepatitis B virus, influenza A and human immunodeficiency virus.

Related Articles

Barclays to pay own $46 million legal bill in Staveley court case

Pfizer to exceed 2021 vaccine production target by as much as 20%, CEO says

Exclusive: Prada's CEO sees 2021 sales growing to 2.9-3.1 billion euros